Clinical trial · Observational
Exploring the Role of Serum Methylmalonic Acid (MMA) in Breast Cancer
A Retrospective Study Exploring the Role of Serum Methylmalonic Acid (MMA) in Breast Cancer---focusing on Metastasis, Chemotherapy Resistance, and Ageing Effects
NCT05352737CI-TRIAL-00059812completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project aims to investigate the role of MMA in breast cancer. To this end, we will measure MMA on serum samples collected at the time of breast cancer diagnosis, to investigate the role of MMA in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| methylmalonic acid testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- Pri-Meta
- description
- patients with breast cancer metastasis at first diagnosis
- interventionNames
- Diagnostic Test: methylmalonic acid testing
- label
- Sec-Meta
- description
- patients with early breast cancer developed distant metastasis within 5 years
- interventionNames
- Diagnostic Test: methylmalonic acid testing
- label
- Non-Meta
- description
- patients with early breast cancer did not develop distant metastasis within 5 years
- interventionNames
- Diagnostic Test: methylmalonic acid testing
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female patients older than 18 years at diagnosis. 2. First diagnosis of invasive breast cancer. 3. All pathological parameters are available to identify histological subtype according to standard procedures. 4. Availability of frozen serum samples at diagnosis. 5. Voluntarily signed Informed Consent obtained before blood drawing for biobanking was performed. Exclusion Criteria: 1. Pregnant at diagnosis. 2. stage 0 disease (in situ). 3. Bilateral BC at diagnosis or multifocal unilateral BC with different histology. 4. Other subtypes than Invasive ductal carcinoma. 5. Prior breast cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.